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INTERACTION OF CLADRIBINE AND FLUDARABINE
WITH GENETIC VARIANTS IN THE CONCENTRATIVE NU-
CLEOSIDE TRANSPORTER, CNT3. I. Badagnani, PharmD, and
K. M. Giacomini, PhD, Department of Biopharmaceutical Sciences,
University of California, San Francisco, CA.
The concentrative nucleoside transporter, CNT3 (SLC28A3), me-
diates the intracellular uptake of the anti-cancer nucleoside analogs,
cladribine and fludarabine. Wide variation in intracellular levels of
these analogs has been described. To test the hypothesis that coding
variants in CNT3 may contribute to this phenotype, we identified and
functionally tested missense variants of CNT3. Ten missense variants
were found in a collection of 256 ethnically diverse DNA samples;
three of these had total allele frequencies 1%. The activity of the
missense variants was determined by isotopic uptake of model
nucleosides in X. laevis oocytes expressing the CNT3 variants. The
rare variant, CNT3-GR, showed an 85% and 83% reduction in the
transport of inosine and thymidine, respectively. All other variants
had similar activity as the reference. There was no difference in the
interaction kinetics of the three common variants with adenosine
when compared to reference (Km6911, 9124, 789, 943 	M
for CNT3, CNT3-SN, -YC and -IV, respectively). These stud-
ies indicate that common missense variants of CNT3 have similar
activities as the reference and suggest that they do not contribute to
variation in intracellular levels of nucleosides and nucleoside ana-
logs. Studies are underway to assess the interaction kinetics of
nucleoside analogs with the common CNT3 variants and to test
whether variation in CNT3 expression contributes to variation in
intracellular levels of nucleoside analogs.
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THE EFFECT OF CYP2D6 GENOTYPE ON THE PHARMA-
COKINETICS OF LOVASTATIN IN CHINESE SUBJECTS. O.
Q. Yin, PhD, Q. Chang, PhD, B. Tomlinson, MD, M. S. Chow,
Pharm D, The Chinese University of Hong Kong, The Chinese
University of Hong Kong, Shatin, NT, Hong Kong.
To investigate whether specific CYP2D6 genotype can influence
the pharmacokinetics of lovastatin, a drug with multi-metabolic path-
way (CYP3A4, 2C9, 2D6 and hydrolysis). A single 40 mg oral dose
of lovastatin was administered to 19 healthy subjects. Multiple blood
samples were collected over 24 h, and plasma concentrations of
lovastatin and lovastatin acid (one of the major metabolites by
hydrolysis) were determined by an LC-MS-MS method. CYP2D6
genotype was determined using PCR followed by restriction enzyme
analysis or allele-specific PCR tests. The subject distribution were: 4
homozygous CYP2D6*1 (*1/*1), 7 heterozygous CYP2D6*10 (*1/
*10 or *2/*10) and 8 homozygous CYP2D6*10 (*10/*10) carriers.
The area under the plasma concentration-time curve (AUC0-24) and
terminal elimination half-life (t1/2) of lovastatin among the three
groups were 12.44.0, 20.210.4 and 30.010.5 ng•h/ml, and
4.40.9, 6.02.4 and 8.12.5 h respectively (one-way ANOVA,
p0.022 for AUC0-24 and p0.046 for t1/2). In comparison to the
homozygous CYP2D6*1 carriers, the oral clearance of lovastatin
were lower by 32.5% (p0.05) and 55.2% (p0.01) in the heterozy-
gous CYP2D6*10 and homozygous CYP2D6*10 carriers respec-
tively. The AUC0-24 of lovastatin acid also tended to be higher in the
heterozygous CYP2D6*10 and homozygous CYP2D6*10 carriers;
however, the difference was not statistically significant. These pre-
liminary results in Chinese subjects show that among extensive
metabolizers of CYP2D6, the pharmacokinetics of lovastatin appears
to be dependent on CYP2D6 genotype.
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THE EFFECT OF POLYMORPHISM ON SEROTONIN AND
HISTAMINE RESEPTOR IN ANTIPSYCHOTIC ACTION OF
OLANZAPINE. T. Amamoto, MD, S. Nakaya, T. Kumai, PhD, Y.
Morokawa, MD, PhD, K. Gen, MD, PhD, H. Suzuki, MD, PhD, T.
Akimoto, MD, A. Aoba, MD, PhD, S. Kobayashi, MD, PhD, St.
Marianna University School of Medicine, Kawasaki, Japan.
PURPOSE: There are individual differences in the effects of
antipsychotic drugs. As the genetic polymorphisms of several resep-
tors are thought to be a cause of individual differences, we investi-
gated the effects of the genetic polymorphisms in serotonin receptors,
histamine receptor and serotonin transporter genes on the clinical
outcome of olanzapine. METHODS: Patients of schizophrenia were
enrolled simultaneously at St. Marianna University hospital with their
written informed consent. In this study was approved by the institu-
tional review board at St. Marianna University School of Medicine.
Patients were given olanzapine (5
20mg) and blood were collected
at 8weeks after drug administration. Clinical symptoms were evalu-
ated by the PANSS scores before drug administration and at
4
8weeks of follow up. Genomic DNA were extracted from periph-
eral blood samples to analyze genetic polymorphisms 5HT2A
(25Thr/Asp, 102T/C, 452His/Tyr, -1438G/A), 5HT2C (23Cys/Ser),
5HTTLPR (-1396 44bp Ins/Del), H2R (-1018G/A), by PCR-RFLP
and the method of direct sequence. RESULTS: The polymorphic
groups of 5HT2A (452His/Tyr, -1438G/A) and 5HT2C (23Cys/Ser)
were prone to present better PANSS scores compared to the wild type
group, whereas the group of 5HT2A(102T/C) showed insignificant
results. It is necessary to analyze more number of cases.
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INTER- AND INTRAINDIVIDUAL VARIABILITY OF URI-
NARY DEXTROMETHORPHAN/DEXTRORPHAN (DM/DX)
RATIOS IN CYP2D6 EXTENSIVE METABOLIZERS (EMS)
WITH ONE OR TWO ACTIVE ALLELES. J. D. Ma, PharmD, J.
S. Bertino Jr., PharmD, A. Gaedigk, PhD, MS, A. D. Kashuba,
PharmD, D. S. Streetman, PharmD, A. N. Nafziger, MD, MHS,
Bassett Healthcare, Children’s Mercy Hospital and Clinics, Univer-
sity of North Carolina, University of Michigan, Cooperstown, NY.
There is significant inter- and intraindividual variability of urinary
DM/DX ratios. Distinguishing between CYP2D6 EMs with one or
two active alleles may explain a portion of the observed variability.
This study evaluated DM/DX ratios in CYP2D6 EMs for 1) differ-
ences by genotype and 2) intraindividual variability. Data from four
previous studies were used. 62 healthy Caucasian adults genotyped
and phenotyped as CYP2D6 EMs (38.67.6 yrs, 19M/40F) were
administered oral DM2 times. 12-16 hour urine collections were
assayed for DM and DX by HPLC. An unpaired t-test was used to
evaluate differences in log-transformed DM/DX ratios by genotype.
Coefficients of variation (CV%) were calculated to examine intrain-
dividual variability of DM/DX ratios and were compared by Wil-
coxon rank-sum test. 38 subjects had 2 active alleles (*1, *2) and 21
had 1 active and 1 null allele (*3, *4, *5). 3 subjects had 1 decreased
activity allele (*10) and were not included. After 30mg of oral DM,
there was no difference in DM/DX ratios [geometric mean (SD)]
between subjects with 2 vs 1 active allele [0.0047 (0.0105, 0.0021) vs
0.0065 (0.0180, 0.0023); p0.23]. After repeated doses of oral DM,
CV% (median, range) of DM/DX ratios were not statistically differ-
ent for those with 2 (41.0%, 4.3-136.6%) vs 1 active allele (44.5%,
6.0-105.5%) (p0.90). Urinary DM/DX ratios cannot distinguish
between CYP2D6 EMs with one or two active alleles.
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